Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kakolyris

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
International Journal of Radiation Oncology, Biology, Physics|April 24, 2001
Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcomeM I Koukourakis, A Giatromanolaki, S Kakolyris, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trialK Alexopoulos, C Kouroussis, N Androulakis, et al.
Oncology|June 26, 2004
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumorsS Kakolyris, J Souglakos, C Kouroussis, et al.
British Journal of Cancer|January 19, 2013
Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancerN Xenidis, M Perraki, S Apostolaki, et al.
Anticancer Research|June 6, 1998
Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomasK Stefanaki, D Rontogiannis, C Vamvouka, et al.
Oncology|July 28, 2001
Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II studyC Kouroussis, J Souglakos, S Kakolyris, et al.
Anticancer Research|May 6, 1998
Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancerA Giatromanolaki, M I Koukourakis, S Kakolyris, et al.
Cancer Research|June 13, 2000
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancerM I Koukourakis, A Giatromanolaki, P E Thorpe, et al.
American Journal of Clinical Oncology|August 24, 2000
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trialD Mavroudis, C Kourousis, N Androulakis, et al.
Oncology Research|November 4, 2000
Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancerA Giatromanolaki, M I Koukourakis, G P Stathopoulos, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
International Journal of Radiation Oncology, Biology, Physics|April 24, 2001
Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcomeM I Koukourakis, A Giatromanolaki, S Kakolyris, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trialK Alexopoulos, C Kouroussis, N Androulakis, et al.
Oncology|June 26, 2004
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumorsS Kakolyris, J Souglakos, C Kouroussis, et al.
British Journal of Cancer|January 19, 2013
Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancerN Xenidis, M Perraki, S Apostolaki, et al.
Anticancer Research|June 6, 1998
Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomasK Stefanaki, D Rontogiannis, C Vamvouka, et al.
Oncology|July 28, 2001
Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II studyC Kouroussis, J Souglakos, S Kakolyris, et al.
Anticancer Research|May 6, 1998
Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancerA Giatromanolaki, M I Koukourakis, S Kakolyris, et al.
Cancer Research|June 13, 2000
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancerM I Koukourakis, A Giatromanolaki, P E Thorpe, et al.
American Journal of Clinical Oncology|August 24, 2000
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trialD Mavroudis, C Kourousis, N Androulakis, et al.
Oncology Research|November 4, 2000
Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancerA Giatromanolaki, M I Koukourakis, G P Stathopoulos, et al.
Pageof 13